PreditX review
A cloud platform for target-specific model building and compound screening, with ADMET triage.
Reviewed by iTechGuides Editors · Editorial team · Updated Oct 2026
PreditX is a cloud-based, no-code platform for early-stage, target-based small-molecule discovery. It is intended for biotech startups, academic research groups, pharma innovation teams, and research institutions that want to build models around a selected biological target and screen compounds for scientific review and experimental planning. Its workflow centers on evidence curation, target-specific machine learning, and candidate prioritization rather than broad discovery across multiple modalities.
The platform automates sourcing, cleaning, and standardization of target-related bioactivity evidence, then trains and evaluates models including Random Forest and XGBoost. Scaffold-aware validation is designed to assess target-specific models, while consensus screening can rank user-submitted molecules or libraries. For teams without a library ready, PreditX offers access to a screening database of over 4.3 million PAINS-free, commercially purchasable compounds. ADMET, structural-alert, and developability triage add context for reviewing shortlisted candidates; reports can be exported as HTML, CSV, or Excel workbooks.
PreditX has a deliberately narrow scope: its discovery focus is target-based, and it does not cover target identification, molecule design, or drug repurposing. Generative AI and molecular design are described as in development, so teams seeking available design-generation functionality should consider another tool. The vendor requests a demo, and pricing is handled through contact with sales; the published product information does not give plan tiers. Cloud deployment and email support suit teams evaluating a hosted workflow, but organizations needing other deployment options or support channels may prefer an alternative. PreditX is most appropriate when compound screening against target-specific models is the priority.
PreditX pros and cons
- Where it wins
- Automates sourcing and standardization of target-related bioactivity evidence
- Validates target-specific models with scaffold-aware splits
- Screens user libraries or over 4.3 million purchasable compounds
- Where it doesn't
- Focused on target-based discovery, not target identification or repurposing
- Molecular design and generative AI are in development
- Requires contacting sales to request a demo
PreditX fact sheet, pricing and score →
Advertiser disclosure: iTechGuides is reader-supported. Vendors can pay for top positions in our rankings and for a place on other products' pages, and we may earn a commission when you click some links. Bought places stand at the number bought; this page and our disclosure say so. Paying vendors may get a fuller, more detailed review from our editors, and that review can change their score. How we rank.
Last updated · How we research and update